Ennis: Fiscal Q4 Earnings Snapshot
MIDLOTHIAN, Texas (AP) — MIDLOTHIAN, Texas (AP) — Ennis Inc. (EBF) on Monday reported earnings of $9 million in its fiscal fourth quarter.
The Midlothian, Texas-based company said it had profit of 35 cents per share.
The clothing and label maker posted revenue of $92.7 million in the period.
For the year, the company reported profit of $40.2 million, or $1.54 per share. Revenue was reported as $394.6 million.
_____
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
CVS is closing 270 pharmacies in 2025. Are any in Wisconsin?
CVS plans to close 270 stores in 2025, joining other pharmacy chains and big box retailers in the U.S who have initiated mass closures in recent months. The Woonsocket, Rhode Island-based company announced the closures in a mid-October press release, CVS Director of External Communications Amy Thibault told the Milwaukee Journal Sentinel. The chain closed 900 stores between 2022 and 2024, after announcing it would reduce its "store density" in November 2021, according to a statement. It currently operates more than 9,000 stores across the U.S. Despite the closures, "85% of people in the U.S. will still live within 10 miles" of a CVS location, according to a CVS statement. The chain also said it has plans to open nearly 30 stores this year. In Wisconsin, three locations closed earlier in 2025, according to Thibault. They were located at: Beloit: 1063 4th St. Milwaukee: 3030 W. Villard Ave. West Allis: 9220 W. Greenfield So, are any other Wisconsin CVS pharmacies planning to shutter this year? Here's what to know: There are not any other planned closures in Wisconsin for 2025, Thibault confirmed. More: Walgreens is closing 500 pharmacies in 2025. Are any in Wisconsin? CVS operates in 48 Wisconsin cities, according to its website. You can find the pharmacy closest to you by using its store locator. This article originally appeared on Milwaukee Journal Sentinel: CVS store closures: Are Wisconsin locations closing?
Yahoo
42 minutes ago
- Yahoo
Here's Why Exelixis (EXEL) is a Strong Growth Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time. Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. EXEL is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 28.5% year-over-year for the current fiscal year, with sales growth of 7.2%. Nine analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.26 to $2.57 per share for 2025. EXEL boasts an average earnings surprise of 48.6%. Looking at cash flow, Exelixis is expected to report cash flow growth of 135.6% this year; EXEL has generated cash flow growth of 10.8% over the past three to five years. Investors should take the time to consider EXEL for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
CLS Outpaces Industry in the Past 3 Months: Reason to Buy the Stock?
Celestica Inc. CLS has gained 24.3% over the past three months compared with the industry's growth of 15.4%. It has also outperformed peers like Flex Ltd. FLEX and Jabil Inc. JBL. Flex has gained 17.3% and Jabil is up 14.7% over this period. With more than two decades of experience in manufacturing backed by a simplified and global network, Celestica is committed to delivering next-generation, cloud-optimized data storage and industry-leading networking AI (artificial intelligence) solutions to help customers balance performance, power efficiency and space as technologies evolve. Operating primarily as a behind-the-scenes partner for other electronics businesses, it is among the lesser-known winners of the AI revolution. The Toronto, Canada-based company offers a one-stop shop for the electronics market, encompassing design, manufacturing and supply chain management. Three-Month CLS Stock Price Performance Image Source: Zacks Investment Research Celestica has benefited from the ongoing generative AI (GenAI) boom, thanks to the solid demand trends for AI/ML (machine learning) compute and networking products from hyperscale customers. In addition to the high-performance 800G family of network switches (which are vital for data centers that power AI applications) and storage solutions like the SC6100 controller and SD6200 platform (which provide efficient and scalable data storage for AI), Celestica offers Photonic Fabric – an optical compute and memory fabric solution capable of supercharging AI infrastructure. This transformational solution provides a foundational technology to advance AI while maintaining scalable, sustainable and profitable business such innovative products, the company has recorded solid revenue growth over the years. By integrating next-generation networking products with silicon photonics packaging solutions, Celestica aims to optimize supply chain solutions to reduce time to market. The data center switches combined with optical transceivers have the potential to handle and sustain high volumes of both inbound and outbound network traffic and cater to the demand for data center bandwidth for supporting AI/ML and data analytics applications. Image Source: Zacks Investment Research Earnings estimates for Celestica for 2025 have moved up 5.7% to $5.05 over the past 60 days, while the same for 2026 has improved 2.4% to $6.07. The positive estimate revision depicts optimism about the stock's growth potential. Image Source: Zacks Investment Research Despite the healthy demand trends, Celestica remains skeptical of the dynamic macro environment owing to trade policy uncertainty. While the environment remains fluid with frequent policy adjustments, recent announcements have provided near-term clarity with the U.S. government offering temporary exemptions for key data center IT hardware, including servers and networking switches, which comprise the majority of its Connectivity & Cloud Solutions (CCS) segment. The company is collaborating with its customers to evaluate the evolving policy landscape and take necessary actions, clouding its near-term revenue prospects. Celestica remains plagued by margin woes. Its products are highly sophisticated and typically based on the latest technological innovations, which have historically led to high research and development costs. High operating expenses have contracted margins. This has dented CLS' prospects to some Celestica faces stiff competition from industry giants like Foxconn, Jabil, Flex and Sanmina Corporation. Several smaller companies operating at a regional level also intensify competition. The highly cyclical nature of the semiconductor industry further remains an overhang. As the company scales up production volumes and costs go down, possible uses for silicon photonics are likely to soar across several industries, including automotive, data center and high-performance computing, telecommunications, medical, aerospace and defense. We believe that Celestica is well-positioned for sustained growth over the years, backed by its robust infrastructure investments, solid technology know-how and wide industry high operating expenses for highly technological products have hurt margins. Although CLS is currently witnessing intense volatility owing to challenging macroeconomic conditions, investors are likely to profit in the long run if they bet on this stock. With a Zacks Rank #3 (Hold), Celestia appears to be treading in the middle of the road, and investors could be better off if they trade with caution. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jabil, Inc. (JBL) : Free Stock Analysis Report Flex Ltd. (FLEX) : Free Stock Analysis Report Celestica, Inc. (CLS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
